EAN News

EAN Scientific Panel Neuro-oncology invites you to take part in their survey:

The first case of COVID-19 infection was recorded in Brazil on Feb 25, 2020. On June 20th, official statistics reported 1 million confirmed cases, and more than 50,000 deaths. Brazil has the second highest number of cases of COVID-19 in the world, facing more than 1,000 deaths per day. However, due to underreporting among many regions in the country, the actual numbers are unknown. Besides the underestimation of the real deaths and cases, the Government recently changed the way in which the cases were reported: only new cases were reported, and not the total number of infected people or deaths. This has produced great criticism from the scientific community and the media, increasing the levels of tension under which the country has been living.

In this paper, just published in the New England Journal of Medicine, the authors report neuropathological findings from autopsies of 18 consecutive patients with SARS-CoV-2 infection who died in a single teaching hospital between April 14 and April 29, 2020.

This retrospective multicentre study aimed to assess the number of patients with acute ischaemic cerebrovascular events seeking inpatient medical emergency care since the implementation of social distancing measures during the COVID-19 pandemic.

In this paper recently published in Neurology, the authors aimed to determine whether neurological manifestations are common in hospitalised COVID-19 patients and to describe their main characteristics.

In this paper, the authors report a case of Guillain-Barré syndrome (GBS) with onset 2 weeks after SARS-CoV-2 infection and highly elevated serum antibodies against SARS-CoV-2, supporting an association between SARS-CoV-2 disease and GBS.

Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In the present COVID-19 pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients.

In this paper, the authors systematically analysed lung tissue samples from 38 patients who died from COVID-19 in two hospitals in northern Italy between Feb 29 and March 24 2020.

In this paper, just published in Lancet, the authors performed a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine in Wuhan, China.

In this paper, the authors investigated the effects of physical distance, face masks, and eye protection on virus transmission in healthcare and non-healthcare settings.

In this paper just published in the New England Journal of Medicine, the authors report the natural history of asymptomatic SARS-CoV-2 infection from part of the cohort of the 410 infected people on the cruise ship, Diamond Princess, who were asymptomatic at the time of testing.

In this paper, the authors conducted a prospective national-level data collection of patients treated with mechanical thrombectomy (MT), across 45 days of pandemic containment measures, compared to patients treated during the same calendar period in 2019.

The winners of the #EAN2020 challenge on Twitter and Instagram during the Virtual Congress have been selected.

From the Spanish Society of Neurology, it is our pleasure to share with our European colleagues the Handbook on COVID-19 management for Neurologists.

On June 3, we published in the Breaking News section of this site the article entitled “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” previously published in Lancet. On June 13, the article was retracted by three of the four authors.